Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

Nature Medicine

Volumn 14, Issue 6, 2008, Pages 617-621

  Watkins, David I ^a,b   Burton, Dennis R ^c   Kallas, Esper G ^d,e   Moore, John P ^f   Koff, Wayne C ^g  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADENOVIRUS 5; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHIMERA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VALIDATION PROCESS; VIRUS INHIBITION; VIRUS LOAD;

AIDS VACCINES; ANIMALS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; TREATMENT FAILURE; VIRAL LOAD; VIRUS REPLICATION;

HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 44949100369     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.f.1759     Document Type: Review

References (76)

1. Baba, T.W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206 (2000).
2. Mascola, J.R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210 (2000).
3. Parren, P.W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
4. Deeks, S.G. & Walker, B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406-416 (2007).
5. VaxGen. VaxGen announces results of its phase 3 HIV vaccine trial in Thailand: vaccine fails to meet endpoints. 〈 http://investor.vaxgen.com/ profiles/investor/ResLibraryView.asp?ResLibraryID=5836&GoTopage=16&BzID= 923&Category=214〉 (2003).
6. Burton, D.R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233-236 (2004).
7. Burton, D.R. et al. Public health. A sound rationale needed for phase 3 HIV-1 vaccine trials. Science 303, 316 (2004).
8. McNeil, J.G., Johnston, M.I., Birx, D.L. & Tramont, E.C. Policy rebuttal. HIV vaccine trial justified. Science 303, 961 (2004).
9. [Anonymous]. HIV vaccine failure prompts Merck to halt trial. Nature 449, 390 (2007).
10. Priddy, F. H. et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46, 1769-1781 (2008).
11. + T cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 79, 13239-13249 (2005).
12. + T lymphocyte selection in simian immunodeficiency virus sequence variation. J. Virol. 78, 14012-14022 (2004).
13. + cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110 (1994).
14. Koup, R.A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
15. Matano, T. et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72, 164-169 (1998).
16. + lymphocytes. Science 283, 857-860 (1999).
17. + T cell depletion in simian immunodeficiency viru-infected macaques. J. Exp. Med. 189, 991-998 (1999).
18. + T cell responses are involved in durable control of AIDS virus replication. J. Virol. 81, 3465-3476 (2007).
19. Leynaert, B., Downs, A.M. & de Vincenzi, I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am. J. Epidemiol. 148, 88-96 (1998).
20. Pilcher, C.D. et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189, 1785-1792 (2004).
21. Wawer, M.J. et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191, 1403-1409 (2005).
22. Quinn, T.C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342, 921-929 (2000).
23. Gray, R.H. et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357, 1149-1153 (2001).
24. Gray, R.H. et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS 17, 1941-1951 (2003).
25. Vogel, T.U. et al. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J. Virol. 77, 13348-13360 (2003).
26. Allen, T.M. et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J. Virol. 76, 4108-4112 (2002).
27. Allen, T.M. et al. Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J. Virol. 76, 10507-10511 (2002).
28. Allen, T.M. et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 164, 4968-4978 (2000).
29. Thakallapally, R. & Kuiken, C. in HIV Molecular Immunology 2000 (eds. Korber, B. et al.) 73-81 (Los Alamos National Laboratory, Los Alamos, 2000).
30. Benson, J. et al. Recombinant vaccine - induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J. Virol. 72, 4170-4182 (1998).
31. Horton, H. et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76, 7187-7202 (2002).
32. Pal, R. et al. ALVAC-SIV-gag-pol-env - based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76, 292-302 (2002).
33. + T cell responses. J. Immunol. 169, 4778-4787 (2002).
34. Hel, Z. et al. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 304, 125-134 (2002).
35. Hel, Z. et al. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J. Immunol. 176, 85-96 (2006).
36. Amara, R.R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA-MVA vaccine. Science 292, 69-74 (2001).
37. Barouch, D.H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
38. Rose, N.F. et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106, 539-549 (2001).
39. Shiver, J.W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415, 331-335 (2002).
40. Feinberg, M.B. & Moore, J.P. AIDS vaccine models: challenging challenge viruses. Nat. Med. 8, 207-210 (2002).
41. Lifson, J.D. & Martin, M.A. One step forwards, one step back. Nature 415, 272-273 (2002).
42. Casimiro, D.R. et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79, 15547-15555 (2005).
43. McDermott, A.B. et al. Cytotoxic T lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J. Virol. 79, 15556-15566 (2005).
44. Mattapallil, J.J. et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J. Exp. Med. 203, 1533-1541 (2006).
45. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312, 1530-1533 (2006).
46. Wilson, N.A. et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80, 5875-5885 (2006).
47. Wyand, M.S., Manson, K.H., Garcia-Moll, M., Montefiori, D. & Desrosiers, R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70, 3724-3733 (1996).
48. Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. & Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941 (1992).
49. Johnson, R.P. et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73, 4952-4961 (1999).
50. Wyand, M.S. et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73, 8356-8363 (1999).
51. Nilsson, C. et al. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12, 2261-2270 (1998).
52. + T lymphocytes following challenge of vaccinated macaques. Virology 333, 226-238 (2005).
53. + T cell responses. Immunity 25, 533-543 (2006).
54. Smith, C.L. et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J. Immunol. 175, 8431-8437 (2005).
55. + T cells shapes the immunodominance hierarchy during boost vaccination. J. Exp. Med. 204, 2187-2198 (2007).
56. Willis, R.A., Kappler, J.W. & Marrack, P.C. CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc. Natl. Acad. Sci. USA 103, 12063-12068 (2006).
57. Chen, W., Anton, L.C., Bennink, J.R. & Yewdell, J.W. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12, 83-93 (2000).
58. Bennett, M.S., Ng, H.L., Dagarag, M., Ali, A. & Yang, O.O. Epitope-dependent avidity thresholds for cytotoxic T lymphocyte clearance of virus-infected cells. J. Virol. 81, 4973-4980 (2007).
59. + T cells: implications for HIV vaccine strategies. J. Immunol. 179, 4571-4579 (2007).
60. + T cells. Blood 107, 4781-4789 (2006).
61. Friedrich, T.C. et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat. Med. 10, 275-281 (2004).
62. Leslie, A.J. et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10, 282-289 (2004).
63. + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178, 2746-2754 (2007).
64. Ali, A. et al. Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J. Virol. 78, 561-567 (2004).
65. Palmowski, M.J. et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168, 4391-4398 (2002).
66. + T cell responses is dramatically modified by DNA immunization and is regulated by γ interferon. J. Virol. 76, 4251-4259 (2002).
67. Yang, O.O. Will we be able to 'spot' an effective HIV-1 vaccine? Trends Immunol. 24, 67-72 (2003).
68. + T cells suppress simian immunodeficiency virus replication. J. Virol. 81, 1517-1523 (2007).
69. + T lymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay. J. Virol. 79, 14986-14991 (2005).
70. Van Baalen, C.A. et al. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J. Virol. 72, 6851-6857 (1998).
71. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71, 3120-3128 (1997).
72. Tomiyama, H., Fujiwara, M., Oka, S. & Takiguchi, M. Cutting Edge: Epitope-dependent effect of Nef-mediated HLA class I down-regulation on ability of HIV-1-specific CTLs to suppress HIV-1 replication. J. Immunol. 174, 36-40 (2005).
73. Gaschen, B. et al. Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360 (2002).
74. + T cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences. J. Virol. 82, 575-581 (2008).
75. Bennett, M.S., Ng, H.L., Ali, A. & Yang, O.O. Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity. J. Infect. Dis. 197, 390-397 (2008).
76. Excler J.L., Rida W., Priddy F., Fast P. & Koff, W. A strategy for accelerating the development of preventive AIDS vaccines. AIDS 21, 2259-2263 (2007).